 BEVERLY, Mass., March 02, 2021 GLOBE NEWSWIRE -- LexaGene Holdings, Inc., TSX-V: LXG; OTCQB: LXXGF the Company, a molecular diagnostics company that develops fully automated rapid pathogen detection systems, announced today that the Company has received approximately 3.6M CAD 2.9M USD in warrant exercises since the start of 2021. 